. 2016 Jun 4;33(7):1094–1104. doi: 10.1007/s12325-016-0355-0

Table 1.

Summary of the characteristics and results from three retrospective cohort (nested case–control) studies assessing the effectiveness of the live-attenuated herpes zoster vaccine, Zostavax, in immunocompetent subjects

Characteristics					Vaccine effectiveness, % (95% CI)
Study ID	Study setting/period	Median follow-up, years	Population	Total/vaccinated subjects	Herpes zoster	Post-herpetic neuralgia	Ophthalmic zoster	Hospitalization for herpes zoster
Tseng et al. [35]	KPSC/2007–2009	1.6	Immunocompetent subjects aged ≥60 years	303,044/75,761	55 (52; 58)	NA	63 (39; 77)	65 (49; 76)
Langan et al. [36]	Medicare/2007–2009	1.6	Immunocompetent and immunocompromised subjects aged ≥65 years	766,330/29,785^a	48 (39; 56)^a	62 (37; 77)^c	NA	NA
Langan et al. [36]	Medicare/2007–2009	1.6		625,409/24,392^b	51 (41; 59)^b	59 (21; 79)^d	NA	NA
Tseng et al. [37]	KPSC/2007–2014	Not reported	Immunocompetent subjects aged ≥60 years	704,312/176,078	51 (50; 53)	NA	NA	NA

KPSC Kaiser Permanente Southern California, CI confidence interval, NA not assessed

^aOverall study population (immunocompetent and immunocompromised subjects)

^bOnly immunocompetent subjects

^cPostherpetic neuralgia at 30 days

^dPostherpetic neuralgia at 90 days